Phase 2 Clinical Trial Clarifies Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease

The results of a phase 2 trial led by Roswell Park's Dr. Brian Betts answer a longstanding question in stem cell transplantation. While adding the JAK inhibitor pacritinib to the treatment regimen for patients undergoing stem cell transplant did not help prevent graft vs. host disease...